Natco Pharma is an Indian multinational pharmaceutical company that manufactures formulations, active pharmaceutical ingredients, and agrochemical products. It is based in Hyderabad and operates in multiple specialty therapeutic areas.
Natco Pharma received CDSCO approval to manufacture and launch generic semaglutide injection in India next month for type 2 diabetes treatment, sending shares up over 11% on Monday.
Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05283226 |
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy |
RECRUITING | PHASE2 |
